



CNPLAW LLP BOOSTS ITS PORTFOLIO OF PRIVATE EQUITY DEALS WITH THE COMPLETION OF THREE NEW TRANSACTIONS

Posted on January 31, 2020

Category: [Deals and cases](#)

General disclaimer

This article is provided to you for general information and should not be relied upon as legal advice. The editor and the contributing authors do not guarantee the accuracy of the contents and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the contents.

Date Published: 31 January 2020

The Lawyers Involved: Lisa Theng, Ken Chia, Hazel Ho-Tsastsina, and Muhammad Parasuram.

CNPLaw LLP's corporate advisory team ended 2019 and started 2020 strong with the completion of three private equity transactions within the food distribution, pharmaceutical and biotechnology industries. Leading the team was CNPLaw LLP's Partner, Mr **Ken Chia**, assisted by Ms **Hazel Ho** (Senior Associate) and Mr **Muhammad Parasuram** (Associate). Managing Partner, Ms **Lisa Theng** was also involved in one of the transactions listed below - CNPLaw acted for a Singapore biotechnology company in its series B funding of S\$15 million from US and Japanese venture capital firms.

The Three Private Equity Deals Completed

1. Acted for one of Japan's leading fresh produce distributors in its investment of over S\$30 million in a Singapore company

On 29 November 2019, CNPLaw LLP finalised a transaction for one of Japan's leading fresh food distributors in its investment of over SG\$30 million in equity and exchangeable debt in a Singapore fresh fruit wholesale trader.

This transaction marks a significant milestone for the client's entry into the Singapore market. Upon the completion of the transaction, the client commended the CNPLaw team for their "quick response".

2. Acted for a Hong Kong listed pharmaceutical company in its investment of S\$2 million in a Singapore biotechnology company

On 5 December 2019, CNPLaw LLP assisted a Hong Kong listed pharmaceutical company to close its investment of S\$2 million in a Singapore biotechnology company. The investment was made by the client's investment arm via the purchase of convertible notes.

The investment contributes towards the advancement of diabetes cell therapy research in Singapore which is currently undertaken by the Singapore biotechnology company.

General disclaimer

This article is provided to you for general information and should not be relied upon as legal advice. The editor and the contributing authors do not guarantee the accuracy of the contents and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the contents.

3. Acted for a Singapore biotechnology company in its series B funding of S\$15 million from US and Japanese venture capital firms

On 2 January 2020, CNPLaw LLP assisted a Singapore biotechnology company involved in cancer research to raise S\$15 million from US and Japanese venture capital firms. This financing round represents the client's series B funding and strategically positions the client for future market entry into the US.

Commenting on the above transactions is Mr Ken Chia:

"We are pleased to service such clients and support their business goals with their global counterparts. The successful completion of these transactions showcases the breadth of our experience across different industries in the private equity/venture capital realm." - Mr Ken Chia, Partner at CNPLaw LLP

General disclaimer

This article is provided to you for general information and should not be relied upon as legal advice. The editor and the contributing authors do not guarantee the accuracy of the contents and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the contents.

General disclaimer

This article is provided to you for general information and should not be relied upon as legal advice. The editor and the contributing authors do not guarantee the accuracy of the contents and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the contents.